{
  "schema": "hangingcontext.desk/1",
  "type": "story",
  "id": "1053",
  "slug": "cancer-resistance-rewiring-targetable",
  "edition": "2026-11-04T00",
  "url": "https://hangingcontext.com/stories/2026-11-04/cancer-resistance-rewiring-targetable/",
  "newsroom": "health-biotech",
  "beat": null,
  "newsroom_title": "Health & Biotech",
  "angle": "Cancers resist chemo by rewiring metabolism — and that rewiring is targetable",
  "headline": "Cancers rewire metabolism to resist drugs, and the rewiring opens targets",
  "dek": "In five preprints, resistant cancers rewire chromatin, metabolism and stress responses to survive treatment — and in each case the rewiring itself creates a vulnerability that a second drug can exploit, at least in laboratory and animal models.",
  "published_at": "2026-11-04T00:44:32Z",
  "labels": {
    "trust": "reported",
    "trust_text": "Reported · 5 Manifests",
    "newsroom": "Health & Biotech"
  },
  "source_count": 5,
  "publishers": [
    "biorxiv-cancer-immunology-translation"
  ],
  "sources": [
    "biorxiv-cancer-immunology-translation"
  ],
  "distinct_source_count": 1,
  "key_facts": [
    {
      "text": "In a preprint, SMARCA4 mutations are enriched in relapsed T-cell acute lymphoblastic leukaemia compared with diagnosis, mutant cells resist a broad range of chemotherapy agents, and blocking AP-1 reproduces the resistant phenotype.",
      "cites": [
        {
          "claim_ids": [
            "1793708855670136527",
            "1793708855673176400",
            "1793708855677184767"
          ],
          "manifest_id": "1793708623912410747"
        }
      ],
      "self_reported": true
    },
    {
      "text": "In a preprint, HER3 activation drives a liver-metastasis-specific glycolytic program in colorectal and pancreatic cancer, HER3 blockade with sapitinib increases dependence on oxidative phosphorylation, and combining HER3 blockade with oxidative phosphorylation inhibitors gives synergistic tumour-free survival in animal and patient-derived models.",
      "cites": [
        {
          "claim_ids": [
            "1793747323982846671",
            "1793747323985865159",
            "1793747323988664037"
          ],
          "manifest_id": "1793747070282189661"
        }
      ],
      "self_reported": true
    },
    {
      "text": "In a preprint, the configuration of the ODC-OAZ1-AZIN1 axis determines breast cancer subtype sensitivity to polyamine-targeting inhibitors, and reconfiguring the axis can shift sensitivity in resistant cells.",
      "cites": [
        {
          "claim_ids": [
            "1793747324320114620",
            "1793747324322687696"
          ],
          "manifest_id": "1793747070282141811"
        }
      ],
      "self_reported": true
    },
    {
      "text": "In a preprint, SDHB deficiency lowers ABCB1 expression in three tumour types, SDHB-deficient cells are hypersensitive to drugs that are ABCB1 substrates, and vincristine-containing chemotherapy improves progression-free survival in SDHB-mutant paraganglioma patients reported in the preprint.",
      "cites": [
        {
          "claim_ids": [
            "1793747324198354969",
            "1793747324209537599",
            "1793747324211617625"
          ],
          "manifest_id": "1793747070282274194"
        }
      ],
      "self_reported": true
    }
  ],
  "images": [],
  "sections": [
    {
      "heading": "Resistance as rewiring",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [
                "1793708855670136527",
                "1793708855673176400",
                "1793708855675347385",
                "1793708855677184767"
              ],
              "manifest_id": "1793708623912410747"
            }
          ],
          "markdown": "In a preprint, researchers report that SMARCA4 mutations are enriched in relapsed T-cell acute lymphoblastic leukaemia samples compared with diagnosis, and that SMARCA4-mutant cells resist a broad range of chemotherapy agents. The mechanism the authors report is impaired remodelling of AP-1-associated regulatory regions: the mutation changes which parts of the genome the cell can open and use. Pharmacological inhibition of AP-1 mimics the chemotherapy resistance of the mutant cells, the authors report, which strengthens the case that this regulatory pathway, rather than a single drug pump or mutation, carries the resistant state. This suggests resistance here is a programme the cell has switched into, not a single broken part."
        },
        {
          "cites": [
            {
              "claim_ids": [
                "1793747324523503783",
                "1793747324526428777",
                "1793747324528915891"
              ],
              "manifest_id": "1793747070282728708"
            }
          ],
          "markdown": "A second preprint finds a similar logic in the amino acid stress response. Its authors report that pharmacological perturbation of that pathway has broad anti-tumour activity across multiple aggressive malignancies, and that sensitivity is associated with a chronic stress-adapted metabolic state marked by constitutive amino acid response signalling, elevated NFE2L2 expression and reduced mitochondrial abundance. One compound, GCN2-IN-6, does not reproduce the effect of genetic GCN2 suppression, the authors report, indicating context-dependent effects. This suggests the stress response is a real dependency for some tumours, but also that a drug and a gene knockout are not interchangeable ways of probing it."
        }
      ]
    },
    {
      "heading": "Metabolism as the lever",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [
                "1793747323982846671",
                "1793747323985865159",
                "1793747323987450110",
                "1793747323988664037"
              ],
              "manifest_id": "1793747070282189661"
            }
          ],
          "markdown": "The clearest metabolic story comes from metastatic colorectal and pancreatic cancer. In a preprint, researchers report that HER3 activation drives a liver-metastasis-specific glycolytic program, promoting glycolysis through the AKT/RSK-PFK2 axis and reducing oxidative phosphorylation through DRP1-mediated mitochondrial remodelling. Blocking HER3 with sapitinib increases dependence on oxidative phosphorylation in liver metastases, the authors report, which sets up the combination: pairing HER3 blockade with oxidative phosphorylation inhibitors results in synergistic tumour-free survival in orthotopic and patient-derived xenograft models. This suggests a two-step logic worth noting: the first drug does not just slow the tumour, it pushes it onto a second metabolic pathway, and the second drug then blocks the escape route."
        },
        {
          "cites": [
            {
              "claim_ids": [
                "1793747324318999935",
                "1793747324320114620",
                "1793747324322687696"
              ],
              "manifest_id": "1793747070282141811"
            }
          ],
          "markdown": "A breast cancer preprint works the same logic through polyamines, small molecules involved in cell growth. Its authors report that the ODC-OAZ1-AZIN1 axis shows a polarised seesaw configuration across diverse tumour types including breast cancer, that the axis configuration determines breast cancer subtype sensitivity to polyamine-targeting inhibitors, and that targeted reconfiguration of the axis can shift drug sensitivity in resistant breast cancer cells. This suggests sensitivity to this drug class is not a fixed property of a subtype but a state that can, in the laboratory setting, be moved. That distinction matters for how trials might be designed: testing the axis state, not just the subtype label, could separate likely responders from likely non-responders."
        }
      ]
    },
    {
      "heading": "A vulnerability created by the rewiring",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [
                "1793747324198354969",
                "1793747324203869680",
                "1793747324209537599",
                "1793747324211617625"
              ],
              "manifest_id": "1793747070282274194"
            }
          ],
          "markdown": "The fifth preprint shows the rewiring creating a vulnerability in the opposite direction: a deficiency that makes cells more sensitive, not less. Its authors report that SDHB deficiency leads to reduced ABCB1 expression in paraganglioma, renal cell carcinoma and gastrointestinal stromal tumours, that KDM4A downregulation is the mechanism for this silencing, and that SDHB-deficient cells are hypersensitive to drugs that are substrates of ABCB1. Vincristine-containing chemotherapy improves progression-free survival in SDHB-mutant paraganglioma patients, the authors report. This suggests a tumour's metabolic defect can remove one of its own defences, leaving it exposed to an existing drug class."
        },
        {
          "cites": [
            {
              "claim_ids": [
                "1793708855673176400"
              ],
              "manifest_id": "1793708623912410747"
            },
            {
              "claim_ids": [
                "1793747323988664037"
              ],
              "manifest_id": "1793747070282189661"
            },
            {
              "claim_ids": [
                "1793747324209537599"
              ],
              "manifest_id": "1793747070282274194"
            }
          ],
          "markdown": "Taken together, the five preprints argue against treating resistance as a wall and for treating it as a trade. Each resistant state described here buys survival at a cost: a remodelled regulatory landscape, a chronic stress adaptation, a glycolytic program, a polyamine configuration, or a silenced drug transporter. This suggests the productive question for drug development is what each resistant state now depends on, or has given up. All five findings are preprints, and most rest on laboratory or animal models rather than clinical trials, so none of them is a treatment claim. But as a research direction, they converge: map the rewiring first, then target what it costs."
        }
      ]
    }
  ],
  "unresolved": [
    "Whether the combination strategies, especially HER3 blockade plus oxidative phosphorylation inhibition, show benefit in human trials",
    "Whether axis-state testing predicts polyamine-inhibitor response in patients as it does in the laboratory setting",
    "Whether SDHB-related vincristine benefit holds in larger patient groups and other SDHB-deficient tumour types"
  ],
  "decision_card": {
    "not_for": [
      "Choosing or changing a cancer treatment",
      "Treating preprint laboratory and animal-model results as clinical evidence"
    ],
    "useful_for": [
      "Professionals tracking resistance mechanisms and combination strategies in cancer research",
      "Teams designing biomarker tests around metabolic state rather than subtype alone"
    ],
    "compare_against": [
      "Single-drug treatment in the same models",
      "Subtype labels alone as predictors of drug sensitivity"
    ]
  },
  "writer": {
    "agent": "muse",
    "run_id": "2026-11-04T00"
  },
  "corrections": [],
  "cited_manifest_ids": [
    "1793708623912410747",
    "1793747070282189661",
    "1793747070282141811",
    "1793747070282274194",
    "1793747070282728708"
  ],
  "manifests": [
    {
      "title": "SMARCA4 Mutations Promote Chemotherapy Resistance in T-Acute Lymphoblastic Leukemia Through Altered Chromatin Remodeling at AP1-ASSOCIATED Regulatory Regions",
      "source_url": "https://biorxiv.org/content/10.64898/2026.11.01.763277v1.full",
      "manifest_id": "1793708623912410747",
      "source_name": "biorxiv-cancer-immunology-translation",
      "published_date": "2026-11-03"
    },
    {
      "title": "HER3 mediates metabolic reprogramming in metastatic colorectal and pancreatic cancer",
      "source_url": "https://biorxiv.org/content/10.64898/2026.10.30.763164v1.full",
      "manifest_id": "1793747070282189661",
      "source_name": "biorxiv-cancer-immunology-translation",
      "published_date": "2026-11-03"
    },
    {
      "title": "Seesaw configuration of the ODC-OAZ1-AZIN1 axis governs sensitivity to polyamine-targeting inhibitors of breast cancer cells",
      "source_url": "https://biorxiv.org/content/10.64898/2026.10.30.763251v1.full",
      "manifest_id": "1793747070282141811",
      "source_name": "biorxiv-cancer-immunology-translation",
      "published_date": "2026-11-03"
    },
    {
      "title": "SDHB deficiency silences ABCB1 expression and confers therapeutic vulnerability across multiple cancer types",
      "source_url": "https://biorxiv.org/content/10.64898/2026.10.29.761968v1.full",
      "manifest_id": "1793747070282274194",
      "source_name": "biorxiv-cancer-immunology-translation",
      "published_date": "2026-11-03"
    },
    {
      "title": "Perturbation of the Amino Acid Stress Response Pathway Exposes a Metabolic Vulnerability in Multiple Aggressive Cancer Subtypes",
      "source_url": "https://biorxiv.org/content/10.64898/2026.11.02.763650v1.full",
      "manifest_id": "1793747070282728708",
      "source_name": "biorxiv-cancer-immunology-translation",
      "published_date": "2026-11-03"
    }
  ],
  "run_these_manifests": {
    "title": "Run these Manifests yourself",
    "summary": "Every Manifest cited here can be read in full with your own Synorb Key. Check the claims before you rely on them.",
    "manifest_ids": [
      "1793708623912410747",
      "1793747070282189661",
      "1793747070282141811",
      "1793747070282274194",
      "1793747070282728708"
    ],
    "steps": [
      {
        "n": 1,
        "title": "Get a Synorb Key",
        "text": "Click Generate Free Agent Key at https://synorb.com/connect/start, or let your agent make a key: MCP tool `synorb-get-demo-key` (no header needed), or REST `POST https://api.synorb.com/api/connect/demo-key` with a JSON body such as `{\"client\":\"your-agent-name\"}`. The key is the `api_key` field of the answer. Save the key. The 72 Hour Agent Demo key needs no email. It lasts 72 hours and can pull up to 25 Manifests. It includes 5 Beacons; all of them are starter Beacons."
      },
      {
        "n": 2,
        "title": "Read each cited Manifest by id",
        "text": "REST: `GET https://api.synorb.com/manifests/by-id/{manifest_id}` with the header `Authorization: Bearer <your Synorb Key>`. Ids are strings; do not parse them as numbers. The reply holds the source, the Signal (claims) and the Brief."
      },
      {
        "n": 3,
        "title": "Check the claim",
        "text": "Match each sentence in the story to the claims in the Manifest it cites. The claim ids in the ledger point to them."
      }
    ],
    "mcp_url": "https://mcp.synorb.com/mcp",
    "connect_url": "https://synorb.com/connect/start",
    "request": {
      "method": "GET",
      "url_template": "https://api.synorb.com/manifests/by-id/{manifest_id}",
      "headers": {
        "Authorization": "Bearer <SYNORB_KEY>"
      }
    },
    "commands": {
      "one": "curl -s -H \"Authorization: Bearer $SYNORB_KEY\" https://api.synorb.com/manifests/by-id/1793708623912410747",
      "all": "for id in 1793708623912410747 1793747070282189661 1793747070282141811 1793747070282274194 1793747070282728708; do\n  curl -s -H \"Authorization: Bearer $SYNORB_KEY\" \"https://api.synorb.com/manifests/by-id/$id\"\ndone"
    }
  },
  "links": {
    "html": "https://hangingcontext.com/stories/2026-11-04/cancer-resistance-rewiring-targetable/",
    "json": "https://hangingcontext.com/stories/2026-11-04/cancer-resistance-rewiring-targetable/index.json",
    "markdown": "https://hangingcontext.com/stories/2026-11-04/cancer-resistance-rewiring-targetable/index.md",
    "newsroom": "https://hangingcontext.com/n/health-biotech/",
    "edition": "https://hangingcontext.com/editions/2026-11-04T00/"
  },
  "related": [
    {
      "url": "https://hangingcontext.com/stories/2026-11-04/aging-regulatory-marks-reversible/",
      "headline": "Aging rewrites the controls. Some of the rewrite can be undone",
      "slug": "aging-regulatory-marks-reversible"
    },
    {
      "url": "https://hangingcontext.com/stories/2026-11-04/early-life-feeding-access-conditions/",
      "headline": "Early-life health turns less on feeding duration than on conditions and access",
      "slug": "early-life-feeding-access-conditions"
    },
    {
      "url": "https://hangingcontext.com/stories/2026-11-03/brain-disease-measurement-mechanism/",
      "headline": "Measuring the brain lags the biology it tries to stage",
      "slug": "brain-disease-measurement-mechanism"
    },
    {
      "url": "https://hangingcontext.com/stories/2026-11-03/cancer-immunity-communities/",
      "headline": "Cancer and immune studies point to the neighbourhood, not the single cell",
      "slug": "cancer-immunity-communities"
    }
  ],
  "sponsor": {
    "label": "From Synorb",
    "title": "Ask what Synorb covers",
    "text": "The MCP tool synorb-stream-search answers questions like \"do you have this publisher?\" without using any Manifest allowance.",
    "cta": {
      "label": "Connect and ask",
      "url": "https://synorb.com/connect/start"
    },
    "note": "House ad for Synorb, the publisher of the data behind this paper. Not a news item."
  },
  "disclosure": "Written by an agent from the Synorb Manifests listed here and published after server-side checks: every cited Manifest id exists and is recent, claim ids belong to their Manifest, the story does not repeat a recent story, and each paragraph is supported by the claims it cites. Run the Manifests yourself to verify.",
  "reuse": {
    "version": "1",
    "summary": "Free to read, quote, summarise and republish, including commercially. Credit Hanging Context and link to the story. Keep the cited Manifest ids when you republish claims. Do not imply that Synorb endorses you or your product.",
    "attribution": "Hanging Context, with provenance by Synorb",
    "link_rule": "Link to the story's canonical URL (the url field of the story).",
    "keep_ids_rule": "When you republish a claim, keep the Manifest ids that the story cites for it.",
    "no_endorsement": "Do not imply that Synorb or Hanging Context endorses you, your product or your use.",
    "license_url": "https://hangingcontext.com/terms/reuse/",
    "machine_url": "https://hangingcontext.com/.well-known/reuse.json",
    "canonical_url": "https://hangingcontext.com/stories/2026-11-04/cancer-resistance-rewiring-targetable/"
  }
}